Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04779749
Other study ID # PregOutCOV
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 8, 2020
Est. completion date September 1, 2021

Study information

Verified date September 2021
Source Brugmann University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A new coronavirus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) appeared in Wuhan, China and it arrived to Europe 2-3 months later. It infected millions of persons and led to the death of thousands until May 2020 where numbers of infections per week decreased significantly. However, starting September, number of infections started to escalate again and continued to rise until now. Hundreds of good quality articles were published during this period to study the relationship and effects of this virus on pregnancy and vice versa, as well as to determine the adverse neonatal and obstetrical outcomes following the infection. In a case-control study using propensity score matching at the level of age, body mass index and comorbidities (diabetes, hypertension, asthma), pregnant women over 20 week's gestation had significantly higher risk for intensive care unit stay, endotracheal intubation, hospitalization for disease related symptoms and need for oxygen therapy. A new systematic review also demonstrated increased risk for ICU admission in pregnant women compared to non-pregnant women and to non-infected pregnant women. On the other hand, many researchers have demonstrated that the rates of preterm delivery and cesarean delivery have increased as well, others reported a close relation between SARS-CoV2 infection and preeclampsia or preeclampsia like condition. Enormous effort was done in order to understand adverse outcomes related to this infection, however, most studies included patients in the third or late second trimester. Few studies stratified adverse outcomes of the patients according to the trimester of infection.


Recruitment information / eligibility

Status Completed
Enrollment 10925
Est. completion date September 1, 2021
Est. primary completion date September 1, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: Pregnant women with viable fetus after 10 weeks' gestation and known pregnancy outcome during the period starting on February 1st 2020 and ending on November 30th 2020. Exclusion Criteria: All ongoing pregnancies, those with unknown outcomes, those terminated medically or voluntary, as well as patients with spontaneous abortion before the 11th gestational week.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Data extraction from medical files
Data extraction from medical files

Locations

Country Name City State
Belgium CHU Brugmann Brussels
France Antoine Béclère Hospital Clamart
France Hôpital Louis Mourier Colombes
Italy Fondazione Policlinico Universitario Agostino Gemelli Roma

Sponsors (1)

Lead Sponsor Collaborator
Brugmann University Hospital

Countries where clinical trial is conducted

Belgium,  France,  Italy, 

References & Publications (7)

Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, Debenham L, Llavall AC, Dixit A, Zhou D, Balaji R, Lee SI, Qiu X, Yuan M, Coomar D, Sheikh J, Lawson H, Ansari K, van Wely M, van Leeuwen E, Kostova E, Kunst H, Khalil A, Tiberi S, Brizuela V, Broutet N, Kara E, Kim CR, Thorson A, Oladapo OT, Mofenson L, Zamora J, Thangaratinam S; for PregCOV-19 Living Systematic Review Consortium. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020 Sep 1;370:m3320. doi: 10.1136/bmj.m3320. — View Citation

Badr DA, Mattern J, Carlin A, Cordier AG, Maillart E, El Hachem L, El Kenz H, Andronikof M, De Bels D, Damoisel C, Preseau T, Vignes D, Cannie MM, Vauloup-Fellous C, Fils JF, Benachi A, Jani JC, Vivanti AJ. Are clinical outcomes worse for pregnant women at =20 weeks' gestation infected with coronavirus disease 2019? A multicenter case-control study with propensity score matching. Am J Obstet Gynecol. 2020 Nov;223(5):764-768. doi: 10.1016/j.ajog.2020.07.045. Epub 2020 Jul 27. — View Citation

Berghella V, Boelig R, Roman A, Burd J, Anderson K. Decreased incidence of preterm birth during coronavirus disease 2019 pandemic. Am J Obstet Gynecol MFM. 2020 Nov;2(4):100258. doi: 10.1016/j.ajogmf.2020.100258. Epub 2020 Oct 15. — View Citation

Cosma S, Carosso AR, Cusato J, Borella F, Carosso M, Bovetti M, Filippini C, D'Avolio A, Ghisetti V, Di Perri G, Benedetto C. Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients. Am J Obstet Gynecol. 2021 Apr;224(4):391.e1-391.e7. doi: 10.1016/j.ajog.2020.10.005. Epub 2020 Oct 8. — View Citation

Khalil A, von Dadelszen P, Draycott T, Ugwumadu A, O'Brien P, Magee L. Change in the Incidence of Stillbirth and Preterm Delivery During the COVID-19 Pandemic. JAMA. 2020 Jul 10. doi: 10.1001/jama.2020.12746. [Epub ahead of print] — View Citation

Mendoza M, Garcia-Ruiz I, Maiz N, Rodo C, Garcia-Manau P, Serrano B, Lopez-Martinez RM, Balcells J, Fernandez-Hidalgo N, Carreras E, Suy A. Pre-eclampsia-like syndrome induced by severe COVID-19: a prospective observational study. BJOG. 2020 Oct;127(11):1374-1380. doi: 10.1111/1471-0528.16339. Epub 2020 Jun 21. — View Citation

Prabhu M, Cagino K, Matthews KC, Friedlander RL, Glynn SM, Kubiak JM, Yang YJ, Zhao Z, Baergen RN, DiPace JI, Razavi AS, Skupski DW, Snyder JR, Singh HK, Kalish RB, Oxford CM, Riley LE. Pregnancy and postpartum outcomes in a universally tested population for SARS-CoV-2 in New York City: a prospective cohort study. BJOG. 2020 Nov;127(12):1548-1556. doi: 10.1111/1471-0528.16403. Epub 2020 Aug 13. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Preterm delivery Delivery at a gestational age < 37 weeks 5 minutes
Primary Preeclampsia Preeclampsia is defined as elevated blood pressure (Systolic blood pressure =140 mmHg or diastolic blood pressure =90 mmHg on at least 2 occasions at least 4 hours apart after 20 weeks of gestation in a previously normotensive patient) and the new onset of 1 or more of the following:
Proteinuria =0.3 g in a 24-hour urine specimen or protein/creatinine ratio =0.3 (mg/mg) (30 mg/mmol) in a random urine specimen or dipstick =2+ if a quantitative measurement is unavailable
Platelet count <100,000/microL
Serum creatinine >1.1 mg/dL (97.2 micromol/L) or doubling of the creatinine concentration in the absence of other renal disease
Liver transaminases at least twice the upper limit of the normal concentrations for the local laboratory
Pulmonary edema
New-onset and persistent headache not accounted for by alternative diagnoses and not responding to usual doses of analgesics
Visual symptoms (eg, blurred vision, flashing lights or sparks, scotomata)
5 minutes
Primary Eclampsia Eclampsia is defined by the occurrence of a grand mal seizure in a woman with preeclampsia in the absence of other neurologic conditions that could cause seizure. 5 minutes
Primary Hemolysis Elevated Liver enzymes Low Platelets Syndrome (HELLP) HELLP syndrome is considered to be a serious complication or variant of preeclampsia in pregnant women. 5 minutes
Primary Number of participants with Cesarean delivery (CD) Number of participants with Cesarean delivery (CD) 5 minutes
Primary Percentage of participants with Cesarean delivery (CD) Percentage of participants with Cesarean delivery (CD) 5 minutes
Primary Deep venous thrombosis diagnosed by imaging tools such as venous Doppler ultrasound of the lower limbs 5 minutes
Primary Pulmonary embolism diagnosed by imaging tools such as angio-CT scan of the thorax. 5 minutes
Primary Pregnancy loss at less than 24 weeks' gestation 5 minutes
Primary Intrauterine Fetal Demise (IUFD) Pregnancy loss at 24 weeks or more, or the delivery of a neonate weighing more than 500 g 5 minutes
Primary Maternal death Maternal death 5 minutes
Primary Low birth weight birth weight at less than 2500g 5 minutes
Primary Number of participants with Neonatal intensive care unit (NICU) admission Number of participants with Neonatal intensive care unit (NICU) admission 5 minutes
Primary Percentage of participants with Neonatal intensive care unit (NICU) admission Percentage of participants with Neonatal intensive care unit (NICU) admission 5 minutes
Primary Number of participants with APGAR score (Activity, Pulse, Grimace, Appearance, Respiration score) at 5 minutes < 7: The score minimum is 0 and maximum is 10. Higher score means better outcome. 5 minutes
Primary Percentage of participants with APGAR score (Activity, Pulse, Grimace, Appearance, Respiration score) at 5 minutes < 7: The score minimum is 0 and maximum is 10. Higher score means better outcome. 5 minutes
Primary Number of participants with Respiratory distress at birth Number of participants with Respiratory distress at birth 5 minutes
Primary Percentage of participants with Respiratory distress at birth Percentage of participants with Respiratory distress at birth 5 minutes
Primary Neonatal death 5 minutes
Secondary Number of participants with Delivery < 32 weeks 5 minutes
Secondary Percentage of participants with Delivery < 32 weeks 5 minutes
Secondary Number of participants with Spontaneous delivery < 37 weeks 5 minutes
Secondary Percentage of participants with Spontaneous delivery < 37 weeks 5 minutes
Secondary Number of participants with Fetal distress referred to bradycardia, recurrent late or variable deceleration on antepartum or intrapartum cardiotocogram. 5 minutes
Secondary Percentage of participants with Fetal distress referred to bradycardia, recurrent late or variable deceleration on antepartum or intrapartum cardiotocogram. 5 minutes
Secondary Number of participants with Unscheduled cesarean delivery 5 minutes
Secondary Percentage of participants with Unscheduled cesarean delivery 5 minutes
Secondary Postpartum hemorrhage defined as the estimated blood loss of > 500 mL 5 minutes
Secondary Number of participants with Intraventricular hemorrhage 5 minutes
Secondary Percentage of participants with Intraventricular hemorrhage 5 minutes
Secondary Umbilical cord pH 5 minutes
Secondary Small for gestational age (SGA) it refers to an estimated fetal weight of less than the 10th percentile 5 minutes
Secondary Large for gestational age (LGA) it refers to an estimated fetal weight of more than the 95th percentile 5 minutes
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3